MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress
-
You are currently browsing the archives for the OncoDaily category.
Pages
- agenT-797, a native allogeneic “off-the-shelf’ iNKT cell therapy product shows anti-tumor activity
- ARDS & Infectious Diseases
- Cancer
- Careers
- Contact
- Engineering
- GvHD
- Homepage
- Identification and characterization of an allogeneic iNKT-CAR Targeting BCMA
- In The News
- iNKT Cells
- Manufacturing
- MiNK Nasdaq ceremony
- MiNK Therapeutics to Present Three Abstracts on Novel Allogeneic iNKT Programs at SITC
- New home banner
- Our Science
- Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-based cell therapy drug product
- Pipeline
- Pipeline OCT 2025 update
- Platform
- Press Releases
- Privacy Policy
- Publications
- Terms and Conditions
Archives
Categories
- EndPoint News (1)
- Investing News Network (1)
- OncoDaily (1)
- Yahoo! Finance (1)
- GlobeNewswire (3)
- Science Daily (1)
- 7 News (1)
- CBS (1)
- LifeScience Leader (1)
- Personalized Medicines Podcast (1)
- Jen – Ted Talk (1)
- CGTlive (4)
- Nasdaq (1)
- Twitter Broadcast with TradeTalks (1)